Kestra Private Wealth Services LLC Reduces Stock Position in Illumina, Inc. $ILMN

Kestra Private Wealth Services LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 52.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,406 shares of the life sciences company’s stock after selling 3,801 shares during the period. Kestra Private Wealth Services LLC’s holdings in Illumina were worth $420,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Capital World Investors boosted its stake in shares of Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp increased its position in Illumina by 3.2% during the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after acquiring an additional 190,324 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares during the period. Geode Capital Management LLC lifted its holdings in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after acquiring an additional 130,139 shares during the period. Finally, Invesco Ltd. lifted its holdings in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after acquiring an additional 1,352,731 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent research reports. Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Piper Sandler raised their price objective on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday. Sanford C. Bernstein began coverage on shares of Illumina in a report on Friday, June 26th. They set a “market perform” rating and a $185.00 target price for the company. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $148.94.

Illumina Price Performance

NASDAQ ILMN opened at $188.68 on Friday. The stock’s 50-day moving average price is $154.74 and its 200-day moving average price is $139.42. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $189.46. The company has a market capitalization of $28.55 billion, a P/E ratio of 34.31, a price-to-earnings-growth ratio of 3.53 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.